Previous reports have addressed the importance of finding ethnicity-specific genes or gene signatures that can explain response, resistance, or toxicities to cancer compounds such as alkylating agents or mAbs (trastuzumab) used for treating breast cancer in HER2+ patients (8, 9). This evidence concerns the gene ERBB2 and breast cancer.